Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1
Status:
Completed
Trial end date:
2017-01-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind study of the efficacy and safety of iclaprim
compared to vancomycin for the treatment of skin and skin structure infections.